SRR1797284
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 50
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.440
- G2M_CHECKPOINT+0.410
- PROTEIN_SECRETION+0.390
- MITOTIC_SPINDLE+0.360
- E2F_TARGETS+0.350
- TGF_BETA_SIGNALING+0.340
- MTORC1_SIGNALING+0.310
- PI3K_AKT_MTOR_SIGNALING+0.310
- PANCREAS_BETA_CELLS+0.290
- ANDROGEN_RESPONSE+0.240
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.310
- KRAS_SIGNALING_DN-0.280
- MYOGENESIS-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- ESTROGEN_RESPONSE_EARLY-0.220
- INTERFERON_GAMMA_RESPONSE-0.220
- TNFA_SIGNALING_VIA_NFKB-0.220
- COAGULATION-0.210
- ESTROGEN_RESPONSE_LATE-0.200
- APICAL_SURFACE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797299 | — | cohortSC | 0.902 |
| 2 | SRR1797288 | — | cohortSC | 0.861 |
| 3 | R144 | — | — | 0.838 |
| 4 | SRR3147744 | — | — | 0.833 |
| 5 | SRR1797280 | — | cohortSC | 0.832 |
| 6 | BS_7G42J2SK | EPN | Supratentorial EPN | 0.829 |
| 7 | SRR33532819 | — | E | 0.824 |
| 8 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.822 |
| 9 | MDT-AP-0155 | Med | Medulloblastoma | 0.818 |
| 10 | MNG730 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.290 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |